Lexicon Appoints Scott Coiante as Chief Financial Officer
Lexicon Pharmaceuticals (LXRX) has appointed Scott Coiante as senior vice president and chief financial officer, effective January 2, 2025. Coiante brings over 35 years of experience in life science and pharmaceutical industries. He previously served as SVP, CFO, and treasurer at Agile Therapeutics from August 2023 to August 2024 and from 2011-2019, where he managed all financial activities including business development and fundraising.
Prior to joining Lexicon, Coiante held positions as SVP, CFO, treasurer, and secretary at Aprea Therapeutics and various senior financial roles at Medarex Inc, supporting its transition after acquisition by Bristol-Myers Squibb. The appointment aligns with Lexicon's strategic shift towards high-impact therapeutic areas and their Lead to Succeed strategy.
Lexicon Pharmaceuticals (LXRX) ha nominato Scott Coiante come vicepresidente senior e direttore finanziario, con effetto dal 2 gennaio 2025. Coiante porta con sé oltre 35 anni di esperienza nei settori delle scienze della vita e farmaceutico. In precedenza, ha servito come SVP, CFO e tesoriere presso Agile Therapeutics da agosto 2023 ad agosto 2024 e dal 2011 al 2019, dove ha gestito tutte le attività finanziarie, comprese sviluppo commerciale e raccolta fondi.
Prima di unirsi a Lexicon, Coiante ha ricoperto ruoli come SVP, CFO, tesoriere e segretario presso Aprea Therapeutics e vari ruoli finanziari senior presso Medarex Inc, supportando la sua transizione dopo l'acquisizione da parte di Bristol-Myers Squibb. La nomina si allinea con il cambiamento strategico di Lexicon verso aree terapeutiche ad alto impatto e la loro strategia Lead to Succeed.
Lexicon Pharmaceuticals (LXRX) ha nombrado a Scott Coiante como vicepresidente senior y director financiero, efectivo el 2 de enero de 2025. Coiante aporta más de 35 años de experiencia en las industrias de ciencias de la vida y farmacéutica. Anteriormente, se desempeñó como SVP, CFO y tesorero en Agile Therapeutics desde agosto de 2023 hasta agosto de 2024 y de 2011 a 2019, donde gestionó todas las actividades financieras, incluido el desarrollo comercial y la recaudación de fondos.
Antes de unirse a Lexicon, Coiante ocupó posiciones como SVP, CFO, tesorero y secretario en Aprea Therapeutics y varios roles financieros senior en Medarex Inc, apoyando su transición tras la adquisición por parte de Bristol-Myers Squibb. La nombramiento se alinea con el cambio estratégico de Lexicon hacia áreas terapéuticas de alto impacto y su estrategia Lead to Succeed.
Lexicon Pharmaceuticals (LXRX)는 Scott Coiante를 수석 부사장 및 최고 재무 책임자로 임명하며, 임기는 2025년 1월 2일부터 시작됩니다. Coiante는 생명 과학 및 제약 산업에서 35년 이상의 경험을 가지고 있습니다. 그는 2023년 8월부터 2024년 8월까지 Agile Therapeutics에서 SVP, CFO 및 재무 담당자로 근무했으며, 2011년부터 2019년까지 모든 재무 활동을 관리했습니다. 여기에는 사업 개발 및 자금 조달이 포함됩니다.
Lexicon에 합류하기 전, Coiante는 Aprea Therapeutics에서 SVP, CFO, 재무 담당자 및 비서로 활동했으며, Medarex Inc에서 여러 고위 재무 역할을 수행하여 Bristol-Myers Squibb에 인수된 후의 전환을 지원했습니다. 이번 임명은 Lexicon의 고임팩트 치료 분야로의 전략적 전환 및 Lead to Succeed 전략과 일치합니다.
Lexicon Pharmaceuticals (LXRX) a nommé Scott Coiante en tant que vice-président senior et directeur financier, effective le 2 janvier 2025. Coiante apporte plus de 35 ans d'expérience dans les secteurs des sciences de la vie et pharmaceutiques. Avant cela, il a été SVP, CFO et trésorier chez Agile Therapeutics d'août 2023 à août 2024 et de 2011 à 2019, où il a géré toutes les activités financières, y compris le développement commercial et la collecte de fonds.
Avant de rejoindre Lexicon, Coiante a occupé des postes de SVP, CFO, trésorier et secrétaire chez Aprea Therapeutics ainsi que divers postes financiers senior chez Medarex Inc, soutenant sa transition après l'acquisition par Bristol-Myers Squibb. Cette nomination s'inscrit dans le cadre du changement stratégique de Lexicon vers des domaines thérapeutiques à fort impact et leur stratégie Lead to Succeed.
Lexicon Pharmaceuticals (LXRX) hat Scott Coiante zum Senior Vice President und Chief Financial Officer ernannt, mit Wirkung zum 2. Januar 2025. Coiante bringt mehr als 35 Jahre Erfahrung in den Bereichen Life Sciences und Pharma mit. Zuvor war er von August 2023 bis August 2024 SVP, CFO und Schatzmeister bei Agile Therapeutics und hatte von 2011 bis 2019 alle finanziellen Aktivitäten, einschließlich Geschäftsentwicklung und Mittelbeschaffung, geleitet.
Bevor er zu Lexicon kam, hatte Coiante Positionen als SVP, CFO, Schatzmeister und Sekretär bei Aprea Therapeutics sowie verschiedene leitende Finanzpositionen bei Medarex Inc inne, wo er den Übergang nach der Übernahme durch Bristol-Myers Squibb unterstützte. Die Ernennung steht im Einklang mit Lexicons strategischem Wandel hin zu Bereichen mit hohem therapeutischen Einfluss und ihrer Lead to Succeed-Strategie.
- Appointment of seasoned CFO with 35+ years of pharmaceutical industry experience
- New CFO brings extensive fundraising and business development expertise
- Strategic alignment with company's focus on high-impact therapeutic areas
- None.
THE WOODLANDS, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the appointment of Scott Coiante as senior vice president and chief financial officer, effective today, January 2, 2025.
Mr. Coiante is a senior finance executive with more than 35 years of experience in the life science and pharmaceutical industries. He joins Lexicon from Agile Therapeutics, where he served as the senior vice president, chief financial officer and treasurer of Agile Therapeutics Inc. from August 2023 to August 2024, as well as from 2011-2019.
“I am pleased to join Lexicon at this pivotal moment for the company and eager to contribute to its ambitious mission of transforming patients’ lives with innovative medicines,” said Mr. Coiante. “I look forward to working with the talented team at Lexicon to drive financial strategies that align with the Company’s vision, support its promising R&D pipeline programs and drive growth.”
During his tenure at Agile Therapeutics, Mr. Coiante was responsible for all financial activities, including supporting business development and fundraising activities. Mr. Coiante also previously served as senior vice president, chief financial officer, treasurer and secretary at Aprea Therapeutics and held several senior financial positions at Medarex Inc, where he supported the transition following the company’s acquisition by Bristol-Myers Squibb. Mr. Coiante has a B.S. from Villanova University.
“We are thrilled to welcome Scott as our new chief financial officer,” said Mike Exton, Ph.D., chief executive officer and director of Lexicon. “His extensive experience aligns with our ongoing shift in strategy to focus on high-impact therapeutic areas. As we continue to refine and execute our Lead to Succeed strategy, Scott will be instrumental in steering Lexicon toward sustainable growth and creating significant value for our shareholders while advancing our R&D programs.”
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has a pipeline of promising drug candidates in discovery and clinical and preclinical development in cardiology, neuropathic pain, metabolism and other indications. For additional information, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, conduct preclinical and clinical development and obtain necessary regulatory approvals of sotagliflozin, LX9211, LX9851 and its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2023 and other subsequent disclosure documents filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
FAQ
Who is the new CFO of Lexicon Pharmaceuticals (LXRX) as of January 2025?
What is Scott Coiante's previous experience before joining LXRX?
How does Scott Coiante's appointment align with LXRX's strategy?
What are Scott Coiante's responsibilities as LXRX's new CFO?
